174
Participants
Start Date
November 30, 2006
Primary Completion Date
July 31, 2009
Study Completion Date
July 31, 2009
certolizumab pegol 400 mg
Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Placebo
Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
Birmingham
Montgomery
Tucson
La Jolla
Oceanside
Orange
Palo Alto
Roseville
Golden
Clearwater
Gainesville
Hialeah
Jacksonville
North Miami Beach
Sarasota
Winter Park
Marietta
Savannah
Chicago
Bloomington
Topeka
Bowling Green
Louisville
Metairie
Annapolis
Newton
Chesterfield
Dearborn
Troy
Rochester
Ocean Springs
Kansas City
Mexico
New York
Syracuse
Chapel Hill
Charlotte
Raleigh
Cincinnati
Cleveland
Dayton
Tulsa
Columbia
Germantown
Austin
Irving
Salt Lake City
Burlington
Chesapeake
Richmond
Seattle
Madison
Milwaukee
Monroe
Calgary
Edmonton
Abbotsford
Vancouver
Winnipeg
Halifax
London
Toronto
Saskatoon
Frankfurt
Heidleberg
Jena
Magdeburg
Ulm
Lead Sponsor
UCB Pharma
INDUSTRY